Issuer directory · Biotechnology · page 2
Biotechnology: issuers 101 to 200 of 832.
Ranked by the amount reported sold on the newest Form D. Page 1 holds the largest raises in the group.
| Issuer | Reported sold | Investors | Exemption | Newest notice | Filings | Platform |
|---|---|---|---|---|---|---|
| Metagenomi Technologies, LLC | $95.8M | 25 | 506(b) | Jan 11, 2023 | 1 | direct |
| Ajax Therapeutics, Inc. | $95.0M | 21 | 506(b) | May 13, 2024 | 1 | direct |
| Newleos Therapeutics, Inc. | $93.4M | 11 | 506(b) | Feb 24, 2025 | 1 | direct |
| Georgiamune, Inc. | $92.7M | 26 | 506(b) | Aug 17, 2026 | 1 | direct |
| Biolinq Inc | $90.0M | 45 | 506(b) | Mar 21, 2025 | 1 | direct |
| Atsena Therapeutics, Inc. | $90.0M | 14 | 506(b) | Apr 11, 2025 | 1 | direct |
| VYNE Therapeutics Inc. | $88.2M | 19 | 506(b) | Nov 16, 2023 | 1 | direct |
| Capstan Therapeutics, Inc. | $87.5M | 21 | 506(b) | Mar 20, 2024 | 1 | direct |
| Perspective Therapeutics, Inc. | $87.4M | 9 | 506(b) | Mar 18, 2024 | 1 | direct |
| Allay Therapeutics, Inc. | $86.9M | 22 | 506(b) | Dec 21, 2023 | 2 | direct |
| Mediar Therapeutics, Inc. | $85.0M | 17 | 506(b) | Oct 22, 2024 | 3 | direct |
| X4 Pharmaceuticals, Inc | $85.0M | 18 | 506(b) | Aug 25, 2025 | 1 | direct |
| Aardvark Therapeutics, Inc. | $85.0M | 31 | 506(b) | May 15, 2024 | 1 | direct |
| Lenz Therapeutics, Inc. | $83.5M | 27 | 506(b) | Mar 10, 2023 | 1 | direct |
| Evozyne, Inc. | $81.0M | 29 | 506(b) | Sep 29, 2023 | 1 | direct |
| NEONC TECHNOLOGIES HOLDINGS, INC. | $80.0M | 67 | 506(b) | Jul 5, 2023 | 1 | direct |
| Elucid Bioimaging Inc. | $79.0M | 13 | 506(b) | Nov 22, 2023 | 1 | direct |
| Dewpoint Therapeutics, Inc. | $77.2M | 23 | 506(b) | Jul 13, 2026 | 2 | direct |
| Tempero Bio, Inc. | $77.0M | 23 | 506(b) | Nov 4, 2025 | 1 | direct |
| Quanta Therapeutics, Inc. | $76.2M | 17 | 506(b) | Jun 24, 2026 | 2 | direct |
| Castle Creek Biosciences, Inc. | $75.0M | 30 | 506(b) | Feb 25, 2025 | 1 | direct |
| Aviceda Therapeutics, Inc. | $75.0M | 17 | 506(b) | Jan 13, 2025 | 2 | direct |
| Therini Bio, Inc. | $74.9M | 17 | 506(b) | Sep 8, 2025 | 2 | direct |
| Septerna, Inc. | $73.5M | 30 | 506(b) | Jul 13, 2023 | 1 | direct |
| EpiBiologics, Inc. | $73.0M | 15 | 506(b) | Apr 25, 2024 | 2 | direct |
| Third Arc Bio, Inc. | $72.5M | 32 | 506(b) | Aug 1, 2024 | 1 | direct |
| FORE US Bio Inc. | $70.4M | 20 | 506(b) | Jul 14, 2026 | 2 | direct |
| EXUMA Biotech Corp. | $70.0M | 26 | 506(b) | Aug 20, 2026 | 1 | direct |
| CARGO Therapeutics, Inc. | $68.8M | 19 | 506(b) | Mar 1, 2023 | 1 | direct |
| Mirum Pharmaceuticals, Inc. | $68.5M | 2 | 506(c) | Jan 29, 2026 | 1 | direct |
| Integrated Biosciences, Inc. | $68.4M | 39 | 506(b) | Aug 5, 2026 | 1 | direct |
| Rezo Therapeutics, Inc. | $68.1M | 21 | 506(b) | Aug 18, 2025 | 3 | direct |
| Imbria Pharmaceuticals, Inc. | $66.7M | 10 | 506(b) | Dec 16, 2025 | 2 | direct |
| Superluminal Medicines, Inc. | $65.5M | 16 | 506(b) | Sep 3, 2026 | 1 | direct |
| Marea Therapeutics, Inc. | $65.4M | 10 | 506(b) | Jun 24, 2024 | 1 | direct |
| Stipple Bio, Inc. | $65.1M | 15 | 506(b) | Apr 6, 2026 | 1 | direct |
| CapsoVision, Inc | $64.8M | 114 | 506(b) | Jul 23, 2024 | 5 | direct |
| EdenRoc Sciences LLC | $64.2M | 50 | 506(b) | Jul 16, 2024 | 2 | direct |
| CoRegen, Inc. | $62.6M | 8 | 506(b) | May 22, 2025 | 1 | direct |
| Enveda Therapeutics, Inc. | $62.5M | 26 | 506(b) | Mar 7, 2023 | 1 | direct |
| Skye Bioscience, Inc. | $62.3M | 12 | 506(b) | Aug 29, 2023 | 1 | direct |
| Garuda Therapeutics, Inc. | $62.1M | 13 | 506(b) | Feb 3, 2023 | 1 | direct |
| AirNexis Therapeutics, Inc. | $62.0M | 13 | 506(b) | Mar 9, 2026 | 1 | direct |
| Redona Therapeutics, Inc. | $60.8M | 11 | 506(b) | Jul 31, 2023 | 3 | direct |
| Alpheus Medical, Inc. | $60.5M | 22 | 506(b) | Jul 30, 2026 | 2 | direct |
| Rani Therapeutics Holdings, Inc. | $60.3M | 15 | 506(b) | Nov 10, 2025 | 1 | direct |
| Volastra Therapeutics, Inc. | $60.2M | 13 | 506(b) | Mar 13, 2023 | 1 | direct |
| Plexium, Inc. | $60.1M | 20 | 506(b) | Aug 25, 2025 | 1 | direct |
| Outlook Therapeutics, Inc. | $60.0M | 21 | 506(b) | Mar 29, 2024 | 1 | direct |
| Nexo Therapeutics, Inc. | $60.0M | 7 | 506(b) | Mar 27, 2026 | 4 | direct |
| ONL Therapeutics, Inc. | $60.0M | 35 | 506(b) | Sep 16, 2024 | 1 | direct |
| Moonwalk Biosciences, Inc. | $60.0M | 7 | 506(b) | Sep 14, 2026 | 1 | direct |
| SOLENO THERAPEUTICS INC | $60.0M | 14 | 506(b) | Oct 4, 2023 | 1 | direct |
| Alto Neuroscience, Inc. | $59.3M | 26 | 506(b) | Nov 27, 2023 | 1 | direct |
| APPLIED DNA SCIENCES INC | $58.0M | 33 | 506(b) | Oct 15, 2025 | 1 | direct |
| TrueBinding, Inc. | $57.7M | 11 | 506(b) | Jul 6, 2023 | 1 | direct |
| Terrestrial Bio, Inc. | $57.3M | 16 | 506(b) | Mar 19, 2026 | 1 | direct |
| Cleveland Diagnostics, Inc. | $56.5M | 26 | 506(b) | Jan 31, 2024 | 1 | direct |
| Typewriter Therapeutics, Inc. | $56.3M | 6 | 506(b) | Sep 21, 2026 | 1 | direct |
| Neuros Medical, Inc. | $56.0M | 28 | 506(b) | Aug 6, 2025 | 1 | direct |
| Outpace Bio, Inc. | $56.0M | 25 | 506(b) | Aug 1, 2024 | 1 | direct |
| Attralus, Inc. | $56.0M | 12 | 506(b) | Feb 9, 2024 | 1 | direct |
| Contraline, Inc. | $55.8M | 77 | 506(b) | Jun 10, 2026 | 1 | direct |
| Claris Biotherapeutics, Inc. | $55.7M | 14 | 506(b) | Aug 12, 2026 | 2 | direct |
| KAZIA THERAPEUTICS LTD | $55.3M | 65 | 506(b) | Dec 18, 2025 | 1 | direct |
| Basking Biosciences, Inc. | $55.0M | 11 | 506(b) | Oct 22, 2025 | 2 | direct |
| Asher Biotherapeutics, Inc. | $55.0M | 16 | 506(b) | Apr 16, 2024 | 1 | direct |
| Kaigene, Inc. | $55.0M | 22 | 506(b) | Oct 14, 2026 | 1 | direct |
| SPRUCE BIOSCIENCES, INC. | $53.6M | 20 | 506(b) | Feb 28, 2023 | 1 | direct |
| Bambusa Therapeutics, Inc. | $53.3M | 16 | 506(b) | Feb 26, 2025 | 1 | direct |
| GLO Pharma, Inc. | $53.0M | 189 | 506(b) | Sep 11, 2023 | 5 | direct |
| Mahzi Therapeutics Inc. | $52.6M | 11 | 506(b) | Jul 8, 2024 | 3 | direct |
| Interius BioTherapeutics, Inc. | $51.4M | 12 | 506(b) | Jun 3, 2024 | 1 | direct |
| Solve Therapeutics, Inc. | $50.4M | 10 | 506(b) | Dec 26, 2024 | 1 | direct |
| Lyra Therapeutics, Inc. | $50.0M | 24 | 506(b) | Jun 9, 2023 | 1 | direct |
| Unicycive Therapeutics, Inc. | $50.0M | 25 | 506(b) | Mar 20, 2024 | 1 | direct |
| Caspian Therapeutics, Inc. | $50.0M | 43 | 506(b) | Sep 23, 2026 | 1 | direct |
| Navigator Medicines, Inc. | $50.0M | 4 | 506(b) | Sep 5, 2024 | 1 | direct |
| Latigo Biotherapeutics, Inc. | $50.0M | 7 | 506(b) | Feb 13, 2025 | 1 | direct |
| Zymeworks Inc. | $50.0M | 2 | 506(b) | Jan 3, 2024 | 1 | direct |
| Cue Biopharma, Inc. | $50.0M | 4 | 506(b) | Jul 22, 2026 | 1 | direct |
| Eledon Pharmaceuticals, Inc. | $50.0M | 24 | 506(b) | May 23, 2024 | 1 | direct |
| CURADEL SURGICAL INNOVATIONS, INC. | $49.8M | 39 | 506(b) | Oct 13, 2026 | 1 | direct |
| Magnus Medical, Inc. | $49.0M | 10 | 506(b) | May 26, 2026 | 2 | direct |
| Clover Biopharmaceuticals, Ltd. | $48.9M | 74 | 506(b) | May 9, 2023 | 3 | direct |
| Adela, Inc. | $48.5M | 11 | 506(b) | Jul 29, 2024 | 2 | direct |
| Character Biosciences, Inc. | $48.2M | 16 | 506(b) | May 12, 2025 | 1 | direct |
| Tasca Therapeutics Corp | $48.1M | 9 | 506(b) | Dec 1, 2025 | 2 | direct |
| SRT Therapeutics, Inc. | $47.4M | 55 | 506(b) | Aug 14, 2025 | 1 | direct |
| Ansa Biotechnologies, Inc. | $46.4M | 41 | 506(b) | Dec 10, 2025 | 2 | direct |
| Axonis Therapeutics, Inc. | $46.0M | 19 | 506(b) | Nov 1, 2024 | 1 | direct |
| CeleCor Therapeutics, Inc. | $45.5M | 11 | 506(b) | Aug 21, 2024 | 3 | direct |
| Spear Bio Inc. | $45.0M | 8 | 506(b) | Aug 5, 2024 | 1 | direct |
| VANQUA BIO, INC. | $45.0M | 12 | 506(b) | Jul 5, 2024 | 1 | direct |
| ImmunoGenesis, Inc. | $44.4M | 88 | 506(b) | Apr 3, 2024 | 1 | direct |
| Nature's Toolbox, Inc. | $44.4M | 19 | 506(b) | Nov 22, 2023 | 1 | direct |
| Atomwise Inc. | $44.3M | 19 | 506(b) | Mar 14, 2025 | 1 | direct |
| Pattern Bioscience, Inc. | $44.2M | 6 | 506(b) | Aug 18, 2025 | 1 | direct |
| Gameto, Inc. | $44.0M | 22 | 506(b) | Aug 26, 2025 | 1 | direct |
| Airway Therapeutics, Inc. | $43.5M | 116 | 506(b) | Sep 9, 2026 | 1 | direct |
